St. Cloud Capital invested Charlotte, NC-based Catawba Research. St. Cloud partnered with a financial investment firm focused on control investments in the life sciences and industrial sectors to support Catawba’s next phase of growth. The investment is out of St. Cloud’s third fund, which has committed capital of $250 million.
“Catawba Research is excited to be a part of the St. Cloud story and we look forward to a successful journey with our new partners. With the support from St. Cloud, Catawba Research is confident of becoming one of the premier global clinical research providers. This is an exciting time for our team and our valued and loyal sponsors,” Zaidoon A. Al-Zubaidy, CEO of Catawba, said.
Catawba is a vertically integrated contract research organization providing clinical management services to pharmaceutical and biotechnology companies globally. The company focuses on Phase II through Phase IV trials across the dermatology, women’s health, ophthalmology and gastroenterology therapeutic areas. Catawba manages clinical end point trials for new drug applications and abbreviated new drug applications. The company has established a global footprint with site relationships across the U.S., Central America and India. Since 2014, Catawba Research has engaged in nearly 50 clinical trials in 13 indications, achieving 15 agency approvals in the U.S. and Canada. The company is headquartered in Charlotte, NC, with additional locations in Texas, New Mexico and Michigan.
“We are extremely pleased with the opportunity at Catawba and look forward to collaborating with management and our financial partners in the Company’s next phase of growth,” Kacy Rozelle, managing partner at St. Cloud Capital, said.
St. Cloud Capital is a Los Angeles, CA-based private investment firm that provides growth capital to the lower middle market (companies with annual revenues generally between $10 million and $150 million) throughout the United States.
